Skip to NavigationSkip to content

Top Ten most popular articles on this week

Published on 03/03/17 at 10:35am

It's been a busy week on over the last seven days. Europe's first biosimilar treatment for cancer continues to resonate throughout the industry, and the week was marked by the shock departure of a number of pharma executives. Also proving popular was our feature on Trump's blusterous first month taking on big pharma - but what threat does he pose to the future of the FDA?

Check out the Top Ten most popular articles on this week!

10. NICE approves first biliary cholangitis drug in 20 years

Ocaliva has been approved by NICE for the treatment of the chronic liver disease primary biliary cholangitis (PBC).

9. Cuba begins Phase 1 testing of HIV vaccine

Cuba once again leads the way with HIV treatment by beginning a trial on a vaccine that would reduce the levels of the virus in the blood without toxic side-effects.

8. Weight loss drug reduces diabetes risk by 80%, according to ICL research

Research shows that use of weight loss drug liraglutide lowers the risk of developing type 2 diabetes by 80% versus placebo.

7. Osteoporosis drugs potentially causing long-term bone weakness

Medication that is used to treat those suffering from weakened bones may actually be causing further damage, new research from scientists at Imperial College London has found.

6. NICE knocks back MSD's Keytruda for lung cancer indication

MSD’s immunotherapy drug Keytruda (pembrolizumab) has been knocked back by NICE for the treatment of untreated PD-L1-positive metastatic lung cancer.

5. First biosimilar for European cancer treatment given approval

The first biosimilar will be made available in Europe to match the indications of Roche’s best-selling cancer drug, Rituxan. 

4. Novo Nordisk's Head of North America resigns

Executive Vice President, Head of North American Operations Jakob Riis has resigned from the company, and will be replaced by current Senior Vice President for Market Access Doug Langa.

3. Does Trump pose a threat to the FDA's future?

President Trump's pledge to slash regulation in the pharma sector by 75% has already drawn concern from industry figures; what effects could his executive orders and overall plan have on the future of the United States' drug regulatory body?

2. Death in trial of Roche’s potential blockbuster haemophilia drug

A death in Roche's trial for its haemophilia medication, emicizumab, is expected to dent confidence in the drug's safety profile.

1. FDA green lights AstraZeneca type-2 diabetes drug

AstraZeneca has announced that its type-2 diabetes treatment Qtern (10mg dapagliflozin and 5mg saxagliptin) has received the approval of the US Food and Drug Administration.

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches